You mean there were investors who were shocked that dental laser maker BioLase Technology
As BioLase forecast, revenue fell 11% to $15 million and net earnings were actually losses of $0.07 per share. The stock fell too, down as much as 9% at its lowest. At around $6.50 a share, BioLase is selling at little more than half of its 52-week highs. Not that it doesn't deserve the discount, but maybe this is a little overdone.
BioLase has a new distributor agreement with Henry Schein
So why is the sell-off an overreaction? BioLase is still the dental laser industry's leader. While its sales declined, the company maintains it did not lose any market share to the competition, which happens to be primarily much smaller companies. Its WaterLase laser is still a strong seller despite the quarter's fall-off -- it represents 74% of all revenues -- and the company has launched a series of disposable components which should provide it with greater revenue diversity in the future. Add in overseas expansion and cost containment initiatives and the rest of the year should come in strong.
That would be in line with management's expectation that the first quarter will be the lowest in revenue for the year, an atypical situation since the second and third quarters are usually the lowest. Investors, therefore, can probably expect 2007 to be generally weak.
For the next few quarters, BioLase says, it will still be training Schein reps, so attention will be diverted from selling, although perhaps not as intensely. It has expanded its distribution agreement in the United Kingdom and will be opening up in Australia and New Zealand. That should serve to complement its operations in Europe and Asia, particularly Korea, which happens to be one of its better-performing foreign markets.
At just 16 times forward earnings, BioLase is trading at significant discounts to aesthetic laser companies like Palomar Medical Technologies
Small-cap growth stories bring a smile to investors every month at Motley Fool Hidden Gems. A 30-day free trial subscription lets you focus on each of the market-beating recommendations that have left subscribers smiling.
Fool contributor Rich Duprey owns shares of Candela but does not have a financial position in any of the other stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.